Insider · CIK 0001282930

GORDON CARL L

Reports to the SEC for 29 companies · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001282930

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-28	ADRXADARx Pharmaceuticals, Inc. · Series C Preferred StockC Conversion	Director, 10% Owner	CConversion	−564K sh	—	—	0
2026-09-28	ADRXADARx Pharmaceuticals, Inc. · Series B-1 Preferred StockC Conversion	Director, 10% Owner	CConversion	−513K sh	—	—	0
2026-09-28	ADRXADARx Pharmaceuticals, Inc. · Series A Preferred StockC Conversion	Director, 10% Owner	CConversion	−10.7M sh	—	—	0
2026-09-28	ADRXADARx Pharmaceuticals, Inc.C Conversion	Director, 10% Owner	CConversion	+1.33M sh	—	—	8,460,994
2026-09-28	ADRXADARx Pharmaceuticals, Inc. · Series B Preferred StockC Conversion	Director, 10% Owner	CConversion	−1.33M sh	—	—	0
2026-09-28	ADRXADARx Pharmaceuticals, Inc.C Conversion	Director, 10% Owner	CConversion	+7.13M sh	—	—	7,127,019
2026-09-28	ADRXADARx Pharmaceuticals, Inc.C Conversion	Director, 10% Owner	CConversion	+10.7M sh	—	—	10,690,530
2026-09-28	ADRXADARx Pharmaceuticals, Inc.P Purchase	Director, 10% Owner	PPurchase	+61.5K sh	$17.00	+$1.05M	9,292,025
2026-09-28	ADRXADARx Pharmaceuticals, Inc. · Series C Preferred StockC Conversion	Director, 10% Owner	CConversion	−256K sh	—	—	0
2026-09-28	ADRXADARx Pharmaceuticals, Inc.P Purchase	Director, 10% Owner	PPurchase	+588K sh	$17.00	+$10M	588,235
2026-09-28	ADRXADARx Pharmaceuticals, Inc.C Conversion	Director, 10% Owner	CConversion	+2M sh	—	—	12,691,492
2026-09-28	ADRXADARx Pharmaceuticals, Inc. · Series A Preferred StockC Conversion	Director, 10% Owner	CConversion	−7.13M sh	—	—	0
2026-09-28	ADRXADARx Pharmaceuticals, Inc. · Series B-1 Preferred StockC Conversion	Director, 10% Owner	CConversion	−770K sh	—	—	0
2026-09-28	ADRXADARx Pharmaceuticals, Inc.C Conversion	Director, 10% Owner	CConversion	+513K sh	—	—	8,974,061
2026-09-28	ADRXADARx Pharmaceuticals, Inc.P Purchase	Director, 10% Owner	PPurchase	+300K sh	$17.00	+$5.1M	14,325,529
2026-09-28	ADRXADARx Pharmaceuticals, Inc.C Conversion	Director, 10% Owner	CConversion	+770K sh	—	—	13,461,093
2026-09-28	ADRXADARx Pharmaceuticals, Inc.C Conversion	Director, 10% Owner	CConversion	+256K sh	—	—	9,230,509
2026-09-28	ADRXADARx Pharmaceuticals, Inc.C Conversion	Director, 10% Owner	CConversion	+564K sh	—	—	14,025,280
2026-09-28	ADRXADARx Pharmaceuticals, Inc. · Series B Preferred StockC Conversion	Director, 10% Owner	CConversion	−2M sh	—	—	0
2026-09-21	ETRAElectra Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+758K sh	—	—	758,279
2026-09-21	ETRAElectra Therapeutics, Inc.P Purchase	Director, 10% Owner	PPurchase	+333K sh	$15.00	+$5M	5,126,891
2026-09-21	ETRAElectra Therapeutics, Inc. · Series A Convertible Preferred StockC Conversion	Director, 10% Owner	CConversion	−2M sh	—	—	0
2026-09-21	ETRAElectra Therapeutics, Inc. · Series C Convertible Preferred StockC Conversion	Director, 10% Owner	CConversion	−1.7M sh	—	—	0
2026-09-21	ETRAElectra Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+2M sh	—	—	2,002,310
2026-09-21	ETRAElectra Therapeutics, Inc.P Purchase	Director, 10% Owner	PPurchase	+1M sh	$15.00	+$15M	1,758,279
2026-09-21	ETRAElectra Therapeutics, Inc. · Series B Convertible Preferred StockC Conversion	Director, 10% Owner	CConversion	−1.09M sh	—	—	0
2026-09-21	ETRAElectra Therapeutics, Inc. · Series C Convertible Preferred StockC Conversion	Director, 10% Owner	CConversion	−758K sh	—	—	0
2026-09-21	ETRAElectra Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+1.09M sh	—	—	3,090,244
2026-09-21	ETRAElectra Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+1.7M sh	—	—	4,793,558
2026-08-10	BLSMBlossomHill Therapeutics, Inc.C Conversion	Director	CConversion	+1.04M sh	—	—	1,039,996
2026-08-10	BLSMBlossomHill Therapeutics, Inc.C Conversion	Director	CConversion	+1.05M sh	—	—	2,089,279
2026-08-10	BLSMBlossomHill Therapeutics, Inc. · Series B Preferred StockC Conversion	Director	CConversion	−1.05M sh	—	—	0
2026-08-10	BLSMBlossomHill Therapeutics, Inc. · Series A Preferred StockC Conversion	Director	CConversion	−1.04M sh	—	—	0
2026-08-10	BLSMBlossomHill Therapeutics, Inc.P Purchase	Director	PPurchase	+625K sh	$16.00	+$10M	2,714,279
2026-08-06	BLSMBlossomHill Therapeutics, Inc. · Director Stock Option (Right to Buy)A Award	Director	AAward	+23.9K sh	—	—	23,904
2026-07-27	SCTXScribe Therapeutics, Inc. · Series B Preferred StockC Conversion	Director	CConversion	−2.07M sh	—	—	0
2026-07-27	SCTXScribe Therapeutics, Inc.P Purchase	Director	PPurchase	+1M sh	$15.00	+$15M	1,348,825
2026-07-27	SCTXScribe Therapeutics, Inc.C Conversion	Director	CConversion	+349K sh	—	—	348,825
2026-07-23	SCTXScribe Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+14.7K sh	—	—	14,725
2026-01-02	CMPXCompass Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+90K sh	—	—	90,000
2025-11-21	KROSKeros Therapeutics, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−74.5K sh	$17.75	−$1.32M	45,057
2025-11-21	KROSKeros Therapeutics, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−140K sh	$17.75	−$2.49M	759,155
2025-06-04	KROSKeros Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+10.5K sh	—	—	10,500
2025-06-04	KROSKeros Therapeutics, Inc.A Award	Director	AAward	+5,250 sh	—	—	5,250
2025-04-09	CMPXCompass Therapeutics, Inc.S Sale	Director	SSale	−3.57M sh	$1.59	−$5.68M	0
2025-02-18	MBXMBX Biosciences, Inc.P Purchase	Director, 10% Owner	PPurchase	+49.1K sh	$10.84	+$532K	3,255,000
2025-02-18	MBXMBX Biosciences, Inc.P Purchase	Director, 10% Owner	PPurchase	+94.1K sh	$10.84	+$1.02M	747,887
2025-02-14	MBXMBX Biosciences, Inc.P Purchase	Director, 10% Owner	PPurchase	+29.5K sh	$9.85	+$291K	3,205,930
2025-02-14	MBXMBX Biosciences, Inc.P Purchase	Director, 10% Owner	PPurchase	+18K sh	$9.90	+$178K	3,176,390
2025-02-11	CMPXCompass Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000

Recent filings

Accepted (ET)
Sep 304
GORDON CARL L0000947871-26-000911
SEC(opens sec.gov)
Sep 234
GORDON CARL L0000947871-26-000881
SEC(opens sec.gov)

Companies

Address

C/O ADARX PHARMACEUTICALS, INC. 5871 OBERLIN DRIVE, SUITE 200

SAN DIEGO, CA, 92121